scholarly journals Retrospective Chart Review Study to Evaluate Health Care Resource Utilization in Patients with Symptomatic Multiple Myeloma in Italy

2016 ◽  
Vol 19 (3) ◽  
pp. A155-A156 ◽  
Author(s):  
S Gonzalez-McQuire ◽  
K Yong ◽  
A Flinois ◽  
C Gazzola ◽  
P Schoen ◽  
...  
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
Resource Utilization ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Health Care Resource ◽  
Health Care Resource Utilization ◽  
Review Study

scholarly journals Chart Review Study to Evaluate Health Care Resource Utilization of Patients with Symptomatic Multiple Myeloma in the United Kingdom

2016 ◽  
Vol 19 (3) ◽  
pp. A156
Author(s):  
S Gonzalez-McQuire ◽  
K Yong ◽  
A Flinois ◽  
C Gazzola ◽  
P Schoen ◽  
...  
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
United Kingdom ◽  
Resource Utilization ◽  
Chart Review ◽  
Health Care Resource ◽  
Health Care Resource Utilization ◽  
The United Kingdom ◽  
Review Study

Treatment patterns, health care resource use and outcomes in metastatic triple-negative breast cancer in Germany: retrospective chart review study (OBTAIN)

2019 ◽  
Vol 35 (8) ◽  
pp. 1405-1414 ◽  
Author(s):  
Jörg Schilling ◽  
Steffi Busch ◽  
Georg Heinrich ◽  
Karin Heinig ◽  
Christian Martin Kurbacher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Health Care ◽  
Triple Negative Breast Cancer ◽  
Resource Use ◽  
Chart Review ◽  
Triple Negative ◽  
Retrospective Chart Review ◽  
Treatment Patterns ◽  
Health Care Resource ◽  
Review Study

scholarly journals Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

Leukemia ◽  
2015 ◽  
Vol 30 (4) ◽  
pp. 995-998 ◽  
Author(s):  
S K Kumar ◽  
E Ma ◽  
A E Engebretson ◽  
F K Buadi ◽  
M Q Lacy ◽  
...  
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
Treatment Outcomes ◽  
Resource Utilization ◽  
Health Care Resource ◽  
Newly Diagnosed ◽  
Health Care Resource Utilization

Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 6621-6621 ◽  
Author(s):  
Hartmut Goldschmidt ◽  
Ravi Vij ◽  
David Kuter ◽  
David Cella ◽  
Teresa Maria Zyczynski ◽  
...  
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
Resource Utilization ◽  
Health Care Resource ◽  
Refractory Multiple Myeloma ◽  
Health Care Resource Utilization

scholarly journals Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan

PLoS ONE ◽  
2021 ◽  
Vol 16 (5) ◽  
pp. e0252124
Author(s):  
Chih-Ning Cheng ◽  
Shang-Yi Huang ◽  
Pei-Wen Lien ◽  
Shih-Ting Huang ◽  
Fang-Ju Lin
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
Resource Utilization ◽  
Real World ◽  
Health Care Resource ◽  
Real World Data ◽  
Health Care Resource Utilization ◽  
Outpatient Visits ◽  
World Information ◽  
One Year

Background We aimed to provide real-world information on survival, health care resource utilization (HCRU), and expenditures related to various first lines of therapy (1LOTs) in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible (TI). Patients and methods From the Taiwan National Health Insurance Database (2008–2016), we identified 1,511 NDMM-TI patients who had received 1LOT since June 2012. We categorized 1LOT regimens into four groups: bortezomib (V)+thalidomide (T), V, T, and non-V/T. Patients’ characteristics were collected. The overall survival (OS), event-free survival (EFS), frequencies of HCRU (hospitalization, visiting outpatient and emergency departments), and related expenditures within one year after commencement of the 1LOT were evaluated and compared. Results The mean age of the included patients was 71.3 (SD 10.7) years, and 40.4% of patients had a CCI score ≥3. Most patients (747; 49.4%) were in the V+T group and, after adjusting for covariates, had a significantly longer OS (median, 22.2 months) and EFS (9.1 months) than those in the T group (12.6 and 4.5 months, respectively) and the non-V/T group (12.2 and 3.2 months, respectively), but they were mostly comparable with patients in the V group (23.8 and 6.6 months, respectively). Compared to those in the V+T group, patients in the T and non-V/T groups had 29% and 39% fewer outpatient visits and 15% and 24% lower total expenditure, respectively. Conclusion Our real-world data consolidate evidence for the effectiveness of bortezomib-containing regimens as the 1LOT in NDMM-TI patients at the expense of more outpatient visits and higher total costs.

10: Adults with Overactive Bladder have Significant Health Care Resource Utilization- Evidence from a Large Medicaid Population

2006 ◽  
Vol 175 (4S) ◽  
pp. 4-4
Author(s):  
Gurkirpal Singh ◽  
Smriti Malla ◽  
Huijian Wang ◽  
Harcharan Gill ◽  
Kristijian H. Kahler ◽  
...  
Keyword(s):  
Health Care ◽  
Overactive Bladder ◽  
Resource Utilization ◽  
Health Care Resource ◽  
Health Care Resource Utilization ◽  
Medicaid Population ◽  
Significant Health
Sign in / Sign up

Export Citation Format

Share Document